European Medicines Agency

Doc. Ref. EMEA/562760/2008
P/97/2008

EUROPEAN MEDICINES AGENCY DECISION

of 3 November 2008

on the application for agreement of a Paediatric Investigation Plan for aprepitant (EMEND), EMEA-000144-PIP01-07 in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

EUROPEAN MEDICINES AGENCY DECISION

of 3 November 2008

on the application for agreement of a Paediatric Investigation Plan for aprepitant (EMEND), EMEA-000144-PIP01-07 in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Merck Sharp & Dohme Ltd. on 07 February 2008 under Article 16(1) of Regulation (EC) No 1901/2006 as amended also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 September 2008, in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended, and Article 13 of said Regulation**,**

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee of the European Medicines Agency, has given a positive opinion,

(2) It is therefore appropriate to adopt a Decision following the Paediatric Committee's opinion on the Paediatric Investigation Plan.

(3) It is therefore appropriate to adopt a Decision granting a waiver

[1] OJ L 378, 27.12.2006, p.1
[2] OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A Paediatric Investigation Plan for aprepitant (EMEND), powder for suspension and hard capsule, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for aprepitant **(**EMEND), powder for suspension and hard capsule, oral use, the details of which are set out in the Opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Merck Sharp & Dohme Ltd., Hertford Road, EN11 9BU Hoddesdon

Done at London, 3 November 2008

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

London, 19 September 2008
Doc. Ref. EMEA/PDCO/466532/2008
EMEA-000144-PIP01-07

POSITIVE OPINION OF THE PAEDIATRIC COMMITTEE ON A REQUEST FOR AGREEMENT OF A PAEDIATRIC INVESTIGATION PLAN FOR

Scope of the application

Active substance:
Aprepitant

Invented name:
EMEND

Condition(s):
Nausea and vomiting

Pharmaceutical form(s):
Powder for suspension
Hard capsule

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
Merck Sharp & Dohme Ltd.

Information about the authorised medicinal product: see Annex II

Basis for opinion

Pursuant to Article 16.1 of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme Ltd. submitted for agreement to the EMEA on 7 February 2008 a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 13 March 2008.

Supplementary information was provided by the applicant on 16 July 2008.

A meeting with the Paediatric Committee took place on 17 September 2008.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended,
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended and concluded in accordance with
  Article 11(1)(a) of Regulation (EC) No 1901/2006 as amended, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population,

The Icelandic and the Norwegian Paediatric Committee members do agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex(es) and appendix(ces).

London, 19 September 2008

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

ANNEX I

THE MEASURES AND TIMELINES OF THE AGREED PAEDIATRIC INVESTIGATION PLAN AND THE SUBSET(S) OF THE PAEDIATRIC POPULATION AND CONDITION(S) COVERED BY THE WAIVER

A. CONDITION(S)

Nausea and vomiting

B. WAIVER

- **Condition**

Nausea and vomiting associated with emetogenic cancer chemotherapy

The waiver applies to:

- Newborn infants (from birth to less than 28 days), Infants (from 28 days to less than 6 months),

for powder for suspension for oral use and for hard capsules for oral use

on the grounds that the specific medicinal product is likely to be unsafe

- **Condition**

Nausea and vomiting associated with postoperative nausea and vomiting

The waiver applies to:

- Newborn infants (from birth to less than 28 days), Infants (from 28 days to less than 6 months),

for powder for suspension for oral use and for hard capsules for oral use

on the grounds that the specific medicinal product is likely to be unsafe

C. PAEDIATRIC INVESTIGATION PLAN

- **Condition to be investigated**

C.1 Nausea and vomiting associated with emetogenic cancer chemotherapy

C.2 Nausea and vomiting associated with postoperative nausea and vomiting

- **Proposed PIP indication**

Prevention of acute and delayed nausea and vomiting associated with moderately or highly emetogenic cisplatin-based cancer chemotherapy in paediatric patients.

Prevention of postoperative nausea and vomiting in paediatric patients.

- **Subset(s) of the paediatric population concerned by the paediatric development**

From 6 months to less than 18 years

- **Formulation(s)**

Powder for suspension, oral use
Hard capsule, oral use

- **Studies**

Area	Number of studies	Description
Quality		Not applicable.
Non-clinical	2	Range-finding juvenile toxicity study in rats (exploratory). Juvenile animal toxicity study
Clinical	3	A multicenter, open-label 3-part study to evaluate the pharmacokinetics, safety, and tolerability of aprepitant in paediatric patients from 6 months to less than 12 years of age receiving emetogenic chemotherapy A multicenter, randomised, double-blind, parallel group, placebo-controlled study to assess the safety and efficacy of aprepitant in the prevention of chemotherapy induced nausea and vomiting in paediatric patients from 12 to less than 18 years of age. A multicenter, two-Part (Part I: open-label PK and Part II: active-comparator-controlled double-blinded efficacy) study to evaluate the pharmacokinetics, safety, and tolerability and exploratory efficacy of aprepitant on nausea and vomiting in paediatric patients from 6 months to less than 18 years of age undergoing surgery

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	**No**
Date of completion of the paediatric investigation plan:	**By December 2011**
Deferral for initiation of some or all studies contained in the paediatric investigation plan:	**No**
Deferral for completion of some or all studies contained in the paediatric investigation plan:	**No**

ANNEX II

INFORMATION ABOUT THE AUTHORISED MEDICINAL PRODUCT

EU Number	Invented name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Content	Package size
EU/1/03/262/001	Emend	80 mg	Capsule, hard	Oral use	blister (alu)		1 capsule
EU/1/03/262/002	Emend	80 mg	Capsule, hard	Oral use	blister (alu)		2 capsules
EU/1/03/262/003	Emend	80 mg	Capsule, hard	Oral use	blister (alu)		5 x 1 capsule
EU/1/03/262/004	Emend	125 mg	Capsule, hard	Oral use	blister (alu)		1 capsule
EU/1/03/262/005	Emend	125 mg	Capsule, hard	Oral use	blister (alu)		5 x 1 capsule
EU/1/03/262/006	Emend	125 mg + 80 mg	Capsule, hard	Oral use	blister (alu)		1 capsule (125 mg) + 2 capsules (80 mg)
EU/1/03/262/007	Emend	40 mg	Capsule, hard	Oral use	blister (alu)		1 capsule
EU/1/03/262/008	Emend	40 mg	Capsule, hard	Oral use	blister (alu)		5 x 1 capsule